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Abstract
Background: We did a bibliometric study on the scientific publications on second-generation antipsychotic drugs 
(SGA) in Hong Kong.
Methods: With the EMBASE and MEDLINE databases, we chose those English articles from Hong Kong. We 
used bibliometric indicators of Price’s law for the increase of scientific literature, and of Bradford’s law for dispersion 
of papers. We also calculated the participation index of the different countries. Then, we correlated those bibliometric 
information with some social and health data (such as total per capita expenditure on health and gross domestic 
expenditure on research and development) of Hong Kong. 
Results: Forty-four original papers were published between 1993 and 2011. Our results indicated non-fulfilment of 
Price’s law (correlation coefficient r=0.5597 after exponential adjustment vs. r=0.6725 after linear adjustment). Those 
most widely studied SGA were clozapine (18 papers), risperidone (11 papers), and olanzapine (4 papers). Division into 
Bradford zones yielded a nucleus occupied by Journal of Clinical Psychopharmacology (4 articles) and Australian and 
New Zealand Journal of Psychiatry (4 articles). A total of 30 different journals were published.
Conclusion: The SGA publications in Hong Kong are still too few to confirm an exponential growth of scientific 
papers. 
*Corresponding author: Dr. Francisco López-Muñoz, Faculty of Health Sciences, 
Camilo José Cela University, C/ Castillo de Alarcón, 49, Urb. Villafranca del 
Castillo, 28692 Villanueva de la Cañada, Madrid, Spain, Tel: 34-91-815-3131; Fax: 
34-91-860-9343; E-mail: francisco.lopez.munoz@gmail.com
Received January 25, 2013; Accepted February 20, 2013; Published February 
25, 2013
Citation: López-Muñoz F, Chung AK, Shen WW, Huelves L, Noriega C, et al. (2013) 
A Bibliometric Study of Scientific Research on Second-Generation Antipsychotic 
Drugs in Hong Kong. Clin Exp Pharmacol 3: 124. doi:10.4172/2161-1459.1000124
Copyright: © 2013 López-Muñoz F, et al. This is an open-access article distributed 
under the terms of the Creative Commons Attribution License, which permits 
unrestricted use, distribution, and reproduction in any medium, provided the 
original author and source are credited.
Keywords: Atypical antipsychotics; Bibliometry; Hong Kong;
Schizophrenia; Second-generation antipsychotics
Introduction
Schizophrenia is a severe mental illness with prevalence ranging 
between 0.5% and 1.0% of the population [1]. The World Health 
Organisation (WHO) lists this illness among the top 10 disorders 
causing a significant disability particularly in the adult population [2].
After the introduction of chlorpromazine [3], the main therapeutic 
pillar for schizophrenia during the last 60 years is antipsychotic 
drugs. The first drugs, called first-generation (classical or typical) 
antipsychotic drugs, show a great efficacy in reducing positive 
symptoms of schizophrenia. But their main limitation is on their 
greater propensity to cause Extrapyramidal Side-Effects (EPS). The 
introduction of clozapine in 1960s in the United States dramatically 
changed the research expectations on antipsychotic drugs. Although 
clozapine had been previously withdrawn from the market due to its 
related agranulocytosis [4], its benefits on causing fewer EPS, having 
efficacy in both positive and negative symptoms from schizophrenia 
as well as its proven efficacy in patients who are refractory to other 
antipsychotic treatments [5], led to the later re-launch of clozapine 
back to the market. In the psychopharmacological aspect, clozapine has 
also opened up the door to the development of the so-called “atypical 
antipsychotics” [6] or Second-Generation Antipsychotic Drugs (SGAs) 
in the next following decades with the introduction of risperidone in 
1993. 
The advances achieved in the development of antipsychotic drugs 
over the past 30 years have been revamped with the clinical use of 
various SGA (Table 1). SGA have notably improved the quality of 
life of psychiatric patients and have contributed decisively to weaken 
the stigmatization that has traditionally accompanied psychiatric 
disorders [7]. After receiving their first licensed indication in treating 
schizophrenia-related disorders, and with their increasingly recognized 
efficacy in treating bipolar disorder, research on SGA have advanced 
considerably as translated into the considerable increase in SGA 
publications worldwide.
Hong Kong is a special administrative region of China, with 
her population reached around 7.07 millions in 2011 (Census and 
Statistics Department, HKSAR, 2012; http://www.census2011.gov.hk/
pdf/summary-results.pdf). As one of the world’s leading international 
financial centres, Hong Kong has a reputable capitalist economy. 
But the mental health policy in Hong Kong has been much less well 
organized. The total number of psychiatric beds in Hong Kong and 
the total number of in-patients treated in public hospitals had been 
reported to be 4,000 and 15,887, respectively in 2008-09. There were 
about 250 practising psychiatrists in Hong Kong as of March 2007, 
giving a psychiatrist-to-population ratio of 2/100,000 at that time 
[8], which was far lower than that of other developed countries like 
Australia (ratio of 14) and Japan (ratio of 9.4). Despite these pitfalls 
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over the last decade, a gradual reform of the mental health services in 
Hong Kong has begun. A better training opportunity in psychiatry has 
driven the increase in the number of registered psychiatric specialists 
to 273 (Hong Kong Medical Council, 2012; http://www.mchk.org.hk/
doctor/Specialist/24.pdf), giving the psychiatrist-to-population ratio 
of 3.9/100,000, a figure more comparable to other Asian developed 
countries like Taiwan (ratio of 4.1). Comprehensive patient care 
services, known as the Personalized Care Program, for patients with 
severe mental illness have also been launched territory-wide since 2012. 
Bibliometric studies are useful tools for assessing the social 
and scientific relevance in a given discipline or field [9]. Our group 
has studied, with a bibliometric approach, the evolution of scientific 
literature in psychiatry by specific research groups, on different 
psychiatric disorders, on aspects related to the discipline, and on 
specific therapeutic tools in the field of psychopharmacology [10-16]. 
Here, we reported the results a bibliometric study on SGA publications 
in Hong Kong. 
Methods
Data sources
The databases used in this bibliometric study were MEDLINE 
(Index Medicus, U.S. National Library of Medicine, Bethesda, 
Maryland, USA) and Excerpta Medica (Elsevier Science Publishers, 
Amsterdam, Netherlands), which are considered the most exhaustive 
databases in the biomedical field. Both databases participate in the 
EMBASE Biomedical Answer web (Elsevier B.V.).
With remote downloading techniques, we selected scientific articles 
published within 1993-2011 containing, in the Author Address (AD) 
section with the descriptor Hong Kong, and in the title (TI) section with 
the descriptors atypic* (atypical*), second-generation antipsychotic*, 
clozapine, risperidone, olanzapine, ziprasidone, quetiapine, sertindole, 
aripiprazole, paliperidone, amisulpride, zotepine, asenapine, 
iloperidone, lurasidone, perospirone and blonanserin. In this study, 
we looked up all the original articles, brief articles, reviews, editorials, 
letters to the editor, and other relevant communications published, 
with all duplicated publications being excluded. 
With manual coding after studying the title and/or abstracts of the 
articles, we also divided those papers into four groups -- “experimental 
pharmacology,” “clinical efficacy,” “tolerance and/or safety,” and “not 
specified group.”
Bibliometric indicators
The Price’s law [17] was applied as the bibliometric indicator of 
production in this study. This law reflects a fundamental aspect in 
scientific paper production, that is, whether its increase is of exponential 
growth. Linear adjustment according to the equation y=0.2982x – 
0.6667 (r2=0.4523), and another adjustment to an exponential curve, 
according to the equation y=0.0003e0.6308x (r2=0.3133) were used for 
the data obtained in order to assess if there was a growth of scientific 
publications on SGAs in Hong Kong and whether such growth followed 
the Price’s law. 
Bradford’s law was also used to assess the dispersion of the scientific 
papers included in this study. With the aim of revealing the distribution 
of the scientific literature in a particular discipline, Bradford proposed 
a model of concentric zones of productivity (Bradford zones) with 
decreasing density of papers [18]. In other words, each Bradford zone 
would contain a similar number of articles, but the number of journals 
in which these articles were published would increase on passing from 
one zone to the next followed. This model permits identification of the 
journals most widely chosen for literature publication, or the journals 
with the greatest weight in a given field publishing scientific literature 
from Hong Kong. 
The Impact Factor (IF) developed by the Institute for Scientific 
Information (Philadelphia, Pennsylvania, USA), which is published 
annually in the Journal Citation Reports (JCR) section of the Science 
Citation Index (SCI), was used as an indicator to reflect the identified 
SGA publication’s repercussion in the current study. IF is widely 
accepted as a quantitative tool for ranking, evaluating, categorizing, and 
comparing academic journals; and in turn, reflecting the quality of the 
submitted manuscripts and the studies reported. It is calculated based 
on a three-year period, and can be regarded as the average number 
of times published papers are cited up to two years after publication 
amongst journal titles sourced in the SCI database. The IF data of 2010 
published in the JCR on 2011 was used in this study. 
The index of collaboration between authors (signatures per 
document or authors per paper index) was also calculated. This index 
shows the quotient between the number of authors and the total 
number of scientific publications collected from the database.
Another indicator applied in this study was the national 
Participation Index (PI) of Hong Kong. PI on SGAs was the ratio 
between the number of articles published on SGAs by the Hong Kong 
researchers and the total number of scientific papers published. This 
PI was used to compare with the global PI in biomedical and health 
sciences, as well as the PI in Psychiatry and Neurology field. Moreover, 
the PI was used to correlate with the total per capita expenditure on 
health, and with the gross domestic expenditure on research and 
development (R&D) obtained from the Organisation for Economic 
and Co-operative Development (OECD) Health Division [19], and 
WHO Department of Health Statistics and Informatics [20]. The 
corresponding PIs from the world’s top 10 countries with the greatest 
scientific research publication outputs during the period of 1997-2011 
were also shown for comparison. 
Results
During the period of 1993-2011, 44 original papers dealing with 
Company Launch
Clozapine Wander Laboratories 1972 * Switzerland
Zotepine Fujisawa 1982 ** Japan
Amisulpride Synthelabo 1986 Portugal
Risperidone Johnson & Johnson 1993 UK / Canada
Sertindole Abbott Laboratories 1996 *** UK
Olanzapine Eli Lilly 1996 USA / UK
Quetiapine AstraZeneca 1997 USA / UK
Ziprasidone Pfizer 2001 USA
Perospirone Dainippon Sumitomo Pharma 2001 Japan
Aripiprazole Otsuka / Bristol-Myers Squibb 2002 USA
Paliperidone Janssen Pharmaceutica 2007 USA
Blonanserin Dainippon Sumitomo Pharma 2008 Japan
Asenapine Schering-Plough 2009 USA
Iloperidone Novartis AG 2009 USA
Lurasidone Dainippon Sumitomo Pharma 2011 USA
* Reintroduced in 1990 in USA and UK after being withdrawn from the market 
since 1975.
** Commercialized by Astellas in Germany in 1990.
*** Marketing authorization was suspended by the European Medicines Agency 
(EMA) in 1998 and the drug was withdrawn from the market. In 2002, based on 
new data, the EMA suggested that sertindole could be reintroduced for restricted 
use with extensive ECG monitoring requirement.
Table 1: Clinical development of second-generation antipsychotic drugs.
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different aspects of SGAs in Hong Kong were retrieved. Of these, 18 
papers were on clozapine, 11 on risperidone, 4 on olanzapine, 3 on 
quetiapine, 3 on paliperidone, 2 on ziprasidone, and 2 on amisulpride 
(some articles study various SGAs as a group and others not mention 
a specific SGA in the TI section). No article concerning aripiprazole, 
sertindole, asenapine, zotepine, iloperidone, lurasidone, perospirone, 
and blonanserin. 
As shown in Figure 1, over the last 20 years there had been only 
a slight increase in the number of publications on SGAs in Hong 
Kong. The mathematical adjustments to the exponential and the linear 
curves confirmed that these data did not meet the postulates of Price’s 
law. Figure 2 showed the growth of SGA papers during the last five-
year period (2007-11) over the previous two five-year periods. The 
cumulative growth of SGAs publications in the previous two five-year 
periods was lower to the total growth of publications in biomedicine 
and health sciences, and in Psychiatry and Neurology. However, there 
noted a higher cumulative increase in publications on SGAs in the 
latest five-year period than the other two fields.
Analysis using the Bradford’s model for journals in which the SGA 
papers were published (Table 2) demonstrated that after discarding 
the last zone, with the expected frequency of 10 articles per Bradford 
zone, the mean number of articles identified was obviously lower. The 
nucleus of the first zone was with articles published in the Journal of 
Clinical Psychopharmacology (n=4 articles) and in the Australian 
and New Zealand Journal of Psychiatry (n=4). The rest of the journals 
analysed was located in zones 2 to 6. Of these 30 different journals, four 
journals, which all had IF greater than 2, had published 31.82% of all 
the identified papers in the current study (Table 3). 
Using manual categorisation, 40.9% of the retrieved publications 
belonged to the “tolerance and safety” group, 34.1% to the “clinical 
efficacy” group, 9.1% to the “experimental pharmacology” group, and 
15.9% to the “not specified” group, concerning pharmacoeconomic 
analysis and prescription patterns. Articles on clinical studies were 
mainly devoted to the diagnosis of schizophrenia (n=9).
The collaboration index (quotient of studies with n co-authors), 
indicative of the collaboration of authors in the preparation of the 
manuscript, was 6.21 authors per paper in the 2007-11 five-year period. 
The collaboration indices were 2.75 in the 1992-96 five-year period, 4 
in the 1997-2001 five-year period, and 6.86 in the 2002-06 five-year 
period. This signified an increase of 125.8% of authors’ collaboration 
when SGA articles were prepared over this 20-year study period.
The contribution of publications on SGAs to biomedicine and 
health sciences in Hong Kong represented a global PI of 0.23 during 
the study period. Table 4 and Figure 3 show the comparisons on 
the proportions of scientific paper publications on SGAs to the 
proportions of publications in biomedicine and health sciences, and 
in the field of Psychiatry and Neurology, between the world’s top 10 
most “productive” countries and Hong Kong. Similar to Japan, another 





























Figure 1: Number of scientific papers on second-generation antipsychotic 
(SGA) drugs from Hong Kong during the study period (1993 - 2011) with 














SGA Hong Kong Psychiatry/Neurology Hong Kong Total Hong Kong
Figure 2: Cumulative growth by five-year periods of scientific literature 
publication in biomedicine and health sciences, on Psychiatry and Neurology, 
and on second-generation antipsychotic drugs from Hong Kong. Each bar 
represents the cumulative increase on the current five-year period over the 
previous five-year period. The baseline period of reference is the five-year 
period of 1992-96. Data are expressed in percentages.
Zones Number of journals Number of articles Bradford’s constants
1 2 8
2 3 8 1.5
3 5 8 1.67
4 8 8 1.6
5 8 8 1
6 4 4
Total number of journals = 30
Average number of articles = 7.33
Average number of articles, excluding the last Bradford zone = 8
Table 2: Distribution of the journals in Bradford’s zones.
Journal Nº Documents PI IF *
Journal of Clinical Psychopharmacology 4 9.09 4.857
Australian and New Zealand Journal of Psychiatry 4 9.09 2.418
International Journal of Neuropsychopharmacology 3 6.82 4.699
Journal of Psychopharmacology 3 6.82 3.801
PI, participation index; IF, impact factor 2010
*Journal Citation Report, 2010 (JCR, 2011).
Table 3: The four journals with the greatest number of publications on second-
generation antipsychotic drugs from Hong Kong.
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Kong appeared occupying only at the bottom rank with respect to SGA 
publications. 
Figure 4 demonstrates the relationship between publication of SGA 
scientific papers and per capita health expenditure, and gross domestic 
expenditure on R&D in Hong Kong, as well as compared to those 
among the world’s 10 most “productive” countries in biomedicine 
and health sciences publications. Despite having moderate per capita 
health expenditure, the relative contribution from Hong Kong on SGA 
studies was small and was well behind the other 10 countries.
Further analyses revealed that the Chinese University of Hong 
Kong had contributed the greatest number of SGAs publications (n=6) 
during the study period, followed by the Queen Mary Hospital (n=5), 
the Castle Peak Hospital (n=4), and the Shatin Hospital (n=4). These 
four centres accounted for 43.18% of the total SGA articles published 
from Hong Kong. 
Discussion
Previous bibliometric studies had drawn attention to a series of 
limitations specific to this sociometric approach [21]. Grey literature 
is one of the common criticisms. Nevertheless, with the extensiveness 
of the two search databases attained, and the diversities in categories of 
the SGA articles generated in our study, the coverage of the publications 
identified should have constituted a more than the representative 
sample of the international research on SGAs from Hong Kong. 
The design of the present analysis permitted a global assessment 
on the growth of SGA scientific publications in Hong Kong. Although 
the number of scientific papers had increased substantially in recent 
years, the growth was not exponential, with the correlation coefficient 
r=0.5597 after exponential adjustment vs. r=0.6725 after linear 
adjustment. Such finding was different from the results of our earlier 
studies from Taiwan [14], South Korea [15] and Japan [16], where both 
showed exponential growths in SGA research publications. Since the 
variety of SGA prescriptions has been demonstrated with a significant 
increase over the years in the Research on Asian Psychotropic 
Prescription (REAP) Project (45.5% in 2001, 64.7% in 2004, and 76.6% 
in 2008) [22], it might be meaningful to understand why Hong Kong 
did not show a similar exponential growth as Taiwan and Japan did. 
We speculated that despite 15 SGAs were included in the current 
literature search, only nine of them, namely, amisulpride, aripiprazole, 
clozapine, olanzapine, paliperidone, quetiapine, risperidone, sertindole 
and ziprasidone have been licensed and available in Hong Kong during 
the study period. This might bound the numbers and variety of SGA 
research carried out in Hong Kong, leading to a small sample size in 
terms of publications identified, and thus limiting the application of 
the Price’s law in this study. 
The surge in scientific research and publications on SGAs appeared 
to coincide with their approved indications for various psychiatric 
disorders from the medicine regulatory agencies, such as the US 
Food and Drug Administration and the European Medicines Agency. 
Previously, Clement et al. [23] had reported that schizophrenia is 
superior to other diagnoses in research activities using the bibliometric 
analysis. Theander and Wetterberg [24] had subsequently reported that 
the number of references on schizophrenia in MEDLINE had followed 
the general increase in medical publications, accounting for 0.42% of 
all medical literature published from 1950 to 2006. Thus, it would not 
be surprising if research in the past on SGAs had been more localized 
on schizophrenia since antipsychotics have always been its mainstay 
of treatment. Nevertheless, except amisulpride, clozapine, paliperidone 
and sertindole, all the other five SGAs (aripiprazole, olanzapine, 
quetiapine, risperidone and ziprasidone) currently available in Hong 
Kong have been licensed in treating bipolar disorder as well [25], 
with quetiapine also acquired its recent approvals as monotherapy 
agent for treating major depressive disorder and generalized anxiety 
disorder. As noted by our earlier studies [14-16], scientific research 
on SGAs has been one of the fastest growing fields in psychiatry. And 
with a growing number in overseas research studies and publications 
on “off-labelled” use of SGAs, including toxic psychosis, agitation 
symptoms, tics disorders, and substance abuse disorders [26,27], it 
could therefore be expected that future bibliometric analysis for SGAs-
related publications from Hong Kong might show a catch-up growth 
following the Price’s law. 
Another aspect of interest for the current study in relation to the 
scientific publication on SGAs from Hong Kong was to investigate 
on its research paper quality. In recent years, journals such as the 
Journal of Clinical Psychopharmacology (IF=4.857), the International 
Journal of Neuropsychopharmacology (IF=4.699), and the Journal of 
Psychopharmacology (IF=3.801) had published SGA-related articles 
from Hong Kong. To note, the top four journals which published more 
than one third of all the identified articles carried the IFs being greater 
than 2.00 having their significant impacts in the field of psychiatry, 
SGA research and their related publications from Hong Kong could 
be regarded as increasingly better in quality and more important 
internationally. 
Both English-speaking countries (the US and the United 
Kingdom) had contributed 39.81% of all the scientific papers in 
Psychiatry & Neurology (Table 4). Housing the headquarters of those 
pharmaceutical companies that are responsible for the development 
of several commonly used SGAs (olanzapine, Eli Lilly; risperidone 
and paliperidone, Janssen Pharmaceutica; quetiapine, AstraZeneca; 
ziprasidone, Pfizer; aripiprazole, Bristol-Myers Squibb/Otsuka 
Pharmaceutical), it might help explain their high PIs. But as illustrated 
in Figure 3, countries such as Canada and Spain had showed a positive 
growth on SGA publications with respect to those in the Psychiatry & 
Neurology field. This might reflect their special interests in research 
on SGAs irrespective to their sites of development. Thus, it would be 
interesting to explore the reason for Hong Kong’s bottom-ranking on 
her PI despite her Excellency in research on early psychosis [8].





1 USA 25.78 35.61 31.84 1.14
2 UK 7.36 9.92 7.97 1.01
3 Japan 6.62 6.82 3.27 0.61
4 Germany 6.30 7.93 6.33 1.02
5 France 4.55 4.93 3.46 0.89
6 China 3.95 2.90 2.00 0.88
7 Italy 3.87 4.76 4.59 1.23
8 Canada 3.67 5.03 5.68 1.44
9 Spain 2.69 2.90 3.93 1.73
10 Australia 2.47 3.07 2.69 1.12
Hong Kong 0.47 0.46 0.23 0.65
Psy-Neurol, area of focus in Neurology and Psychiatry; SGAs, second-generation 
antipsychotic drugs.
* The world’s top 10 most productive countries in biomedicine and health sciences 
for the period 1993-2011. 
** The “productivity” in the discipline of Psychiatry and Neurology. 
Total documents 1993-2011: 13,746,667
Total documents in Neurology & Psychiatry Area 1993-2011: 1,471,156
Table 4: Distribution of literature on second-generation antipsychotic drugs from 
the world’s top 10 most productive countries in biomedicine and health sciences 
compared to Hong Kong for the study period (1993-2011).
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Figure 3: Graphical representation on the comparisons on publications on second-generation antipsychotic drugs to those in the field of Psychiatry and Neurology 
between the world’s top 10 most productive countries in biomedicine and health sciences and Hong Kong. 



















































Per capita Health Expenditure (PI/Total Health Expenditure per capita) x 1000000 PI/Gross Domestic Expenditure on R&D
Figure 4: Per capita health expenditure and its relationship between publications of scientific literature on second generation antipsychotic drugs and per capita health 
expenditure and gross domestic expenditure in relations to research and development among the world’s top 10 most productive countries in biomedicine and health 
sciences compared to those from Hong Kong. 
PI, participation index.
Total Health Expenditure per capita PPP US $, data from Organisation for Economic and Cooperative Development 2009 [19].
Japan and Australia; Data 2008
China: Total Health Expenditure per capita PPP Int $ (data 2008) [20].
Hong Kong: Total Health Expenditure per capita US $ (data Department of Health: http://www.dh.gov.hk/english/statistics/statistics_hs/files/Health_Statistics_
pamphlet_E.pdf).
Gross Domestic Expenditure on R & D (%). Data OECD 2010, except USA and Japan (data 2009) and China (data 2007).
Hong Kong: Data of Census and Statistical Department (http://www.censtatd.gov.hk/hong_kong_statistics/statistics_by_subject/index.jsp?subjectID=7&charsetID = 
1&displayMode=T).
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The correlation of scientific papers on SGAs with the per capita 
health expenditure for each country (Figure 4) might offer another 
explanation of the phenomenon on why Hong Kong had a low PI 
on SGA research. In general, one would expect that the higher the 
expenditure on health, the greater would be the health research-
related activities. It was therefore striking to observe such low ratios 
for countries such as Australia, France, and especially for Hong Kong. 
Being one of the world’s highest gross domestic product per capita city 
(PPP US$ 49,137), Hong Kong has been reported only having 5.5% 
of her gross domestic product spent on healthcare, out of which only 
about 0.24% distributed to mental health [8]. The correlation analysis 
between the scientific SGA research publications and the gross domestic 
expenditure on SGA research and development in our current study 
also demonstrated such an exceptionally low ratio for Hong Kong. The 
lack of public research funding in Hong Kong reported by Cheung et 
al. [8] might have pinpointed the core of this situation.
Limitations and strengths of the study
Readers might have to be cautioned against generalizing the 
current study findings because this study has three major limitations 
in common to other bibliometric studies [20]. First, not all SGA papers 
from Hong Kong were included in this study. This bibliometric study 
included papers retrieved only from the EMBASE Biomedical Answer 
web. The search fields constrained by the databases themselves have 
restrained the subsequent development of the studied materials 
[28,29]. We might then have excluded those papers on SGAs if the 
authors have not put our study inclusion descriptors in the titles or as 
key words. Moreover, local journals that are not indexed in MEDLINE 
and Excerpta Medica during the study period, and those contributions 
from Hong Kong’s investigators at scientific conferences and meetings 
were also not included in our current study [29]. In fact, the East Asian 
Archives of Psychiatry (previously titled as the Hong Kong Journal 
of Psychiatry before March 2010), which is the official peer-reviewed 
publication of the Hong Kong College of Psychiatrists since 1991, has 
only be indexed in MEDLINE since 2011. Second, in the AD section 
using the descriptor “Hong Kong”, we included those papers with 
authors specifying “Hong Kong” in their addresses only. We did not 
count those papers as Hong Kong papers if the contributor authors 
from Hong Kong had not put their Hong Kong addresses. Finally, 
the use of the SCI impact factor to determine the merit or quality of 
scientific contributions is still debatable. The citation count applied in 
calculating the impact factor may not directly reflect the importance or 
quality of one study; on the contrary, it may only represent the topic of 
a given study being “more fashionable”, or even “not yet mature” and/
or “in need of more studies”. This might explain why most universities 
of the United States, unlike those in Europe and in Asia, do not usually 
use impact factor to evaluate the academic outputs of their faculty 
members. 
Nevertheless, in spite of the above-listed major limitations swirling 
around bibliometric studies, they are still considered useful in assessing 
the social and scientific relevance of a given discipline or field [9]. 
Bibliometric studies remain to be important in constituting an effective 
complement for the opinions and judgments of experts in each field, in 
providing a useful and objective measure to evaluate the results of the 
scientific activity, in offering a more realistic view of the global picture 
and as an indication of the trends of research in one specific discipline, 
as well as in predicting how the research activity might evolve for a 
given scientific speciality [30]. 
In conclusion, our current study offered an opportunity to 
unveil the recent changes of the representativeness and growth of 
publications concerning the research on SGAs in Hong Kong. Having 
demonstrated the better quality and wider dissemination of scientific 
research literature on SGAs from Hong Kong, it could be expecting 
that research in this field would possibly continue to grow in the future 
since the “ideal” antipsychotic drug has not yet been found [7], that 
etiopathogeny of schizophrenia remains unclear, and there have been 
broader licensed indications for SGAs used in treating psychiatric 
disorders in Hong Kong. 
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